New York Assembly Bill A10045

New York 2025-2026 Regular Session

• Introduced: 1/30/26
• Refer: 1/30/26
• Report Pass: 4/28/26
• Refer: 4/28/26

Caption

Establishes an awareness campaign on the use of hormone replacement therapy in treating the symptoms of perimenopause and menopause

Summary

A10045 would amend the Public Health Law to create a state awareness campaign about hormone replacement therapy (HRT) for people experiencing perimenopause and menopause. The campaign would be required to provide information on perimenopause and menopause symptoms, potential health risks, the types of HRT available, and the benefits, risks, side effects, and current recommendations for use. The bill is framed as a public education measure rather than a direct treatment mandate or insurance coverage change. The bill would add a new topic to the Department of Health’s public health education responsibilities under section 207 of the Public Health Law. It would require the state to disseminate medically relevant information about HRT and related menopausal health issues, and it authorizes any necessary implementing rules or regulations to be adopted before the effective date. The act would take effect 60 days after becoming law. The available legislative history suggests generally favorable sentiment. The Assembly Health Committee approved the bill unanimously, 25-0, and advanced it to Ways and Means, indicating broad support at least at the committee level. The bill later passed the Senate, which further suggests it moved through the Legislature without major recorded opposition. No committee transcript is available, so there is little direct evidence of detailed debate or objections. Based on the bill’s subject matter, any contention would likely center on the medical framing of hormone replacement therapy, the balance of benefits and risks presented in the campaign, or whether the state should be promoting information on a treatment that has historically been viewed cautiously in some contexts. However, the recorded vote history does not show significant controversy.

Impact

The bill would expand New York’s public health education mandate by requiring the Department of Health to include hormone replacement therapy, perimenopause, and menopause in its awareness efforts. It does not change eligibility for treatment, regulate providers, or create a new benefit mandate; instead, it adds an informational campaign topic under the Public Health Law. The practical effect would be to direct state health messaging toward middle-aged and older women and others affected by menopausal symptoms, potentially increasing public awareness of treatment options and associated risks.

Sentiment

The recorded sentiment is positive and largely noncontroversial. The Assembly Health Committee voted unanimously in favor, and the bill subsequently passed the Senate, indicating bipartisan or at least broad legislative comfort with the measure. The absence of recorded dissent or negative committee discussion suggests the bill was viewed as a straightforward public health education initiative rather than a contentious policy change.

Contention

There is no documented committee debate in the provided materials, so no specific objections are recorded. Any likely points of contention would involve how hormone replacement therapy is characterized, whether the campaign should emphasize risks versus benefits, and whether state resources should be used to promote awareness of a treatment that has had mixed public perceptions. The available vote history, however, shows no measurable opposition in committee and no clear sign of organized resistance in the legislative process.